Inhibikase Therapeutics Stock Revenue
| IKT Stock | USD 1.60 0.08 5.26% |
Inhibikase Therapeutics' fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Inhibikase Stock price.
| Last Reported | Projected for Next Year |
Inhibikase | Revenue | Build AI portfolio with Inhibikase Stock |
Inhibikase Therapeutics Company Revenue Analysis
Inhibikase Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Inhibikase
Projected quarterly revenue analysis of Inhibikase Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Inhibikase Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Inhibikase Therapeutics' stock price.
Inhibikase Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Inhibikase Therapeutics is extremely important. It helps to project a fair market value of Inhibikase Stock properly, considering its historical fundamentals such as Revenue. Since Inhibikase Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inhibikase Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inhibikase Therapeutics' interrelated accounts and indicators.
| -0.32 | 0.33 | -0.65 | -0.51 | -0.71 | ||
| -0.32 | 0.32 | 0.48 | 0.91 | 0.54 | ||
| 0.33 | 0.32 | -0.26 | 0.06 | -0.03 | ||
| -0.65 | 0.48 | -0.26 | 0.48 | 0.62 | ||
| -0.51 | 0.91 | 0.06 | 0.48 | 0.56 | ||
| -0.71 | 0.54 | -0.03 | 0.62 | 0.56 |
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Inhibikase Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Inhibikase Therapeutics reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Inhibikase Therapeutics is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 72.66 Million. Inhibikase Therapeutics adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.Inhibikase Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Inhibikase Therapeutics from analyzing Inhibikase Therapeutics' financial statements. These drivers represent accounts that assess Inhibikase Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inhibikase Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 102.5M | 55.7M | (13.7M) | (1.8M) | (2.0M) | (1.9M) |
Inhibikase Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Inhibikase Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Inhibikase Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Inhibikase Therapeutics' value.| Shares | Susquehanna International Group, Llp | 2025-03-31 | 504.6 K | Blackrock Inc | 2025-03-31 | 424 K | Geode Capital Management, Llc | 2025-03-31 | 324.8 K | Goldman Sachs Group Inc | 2025-03-31 | 166 K | Blair William & Co | 2025-06-30 | 157 K | Marshall Wace Asset Management Ltd | 2025-03-31 | 155.3 K | Jane Street Group Llc | 2025-03-31 | 116.2 K | Barclays Plc | 2025-03-31 | 84 K | Balyasny Asset Management Llc | 2025-03-31 | 81.2 K | Sands Capital Ventures, Llc | 2025-03-31 | 10.9 M | Soleus Capital Management, L.p. | 2025-03-31 | 6.3 M |
Inhibikase Fundamentals
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | 19.15 M | ||||
| Shares Outstanding | 74.34 M | ||||
| Shares Owned By Insiders | 13.02 % | ||||
| Shares Owned By Institutions | 74.47 % | ||||
| Number Of Shares Shorted | 3.07 M | ||||
| Price To Book | 1.31 X | ||||
| Price To Sales | 1,000,000 X | ||||
| Gross Profit | (24.97 M) | ||||
| EBITDA | (27.49 M) | ||||
| Net Income | (27.52 M) | ||||
| Cash And Equivalents | 32.21 M | ||||
| Cash Per Share | 1.28 X | ||||
| Total Debt | 110.52 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.56 X | ||||
| Book Value Per Share | 1.15 X | ||||
| Cash Flow From Operations | (19.15 M) | ||||
| Short Ratio | 5.78 X | ||||
| Earnings Per Share | (0.58) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 15 | ||||
| Beta | 0.91 | ||||
| Market Capitalization | 113.75 M | ||||
| Total Asset | 98.6 M | ||||
| Retained Earnings | (94.42 M) | ||||
| Working Capital | 94.72 M | ||||
| Net Asset | 98.6 M |
About Inhibikase Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inhibikase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibikase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibikase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.